Company profile
Viatris Inc.
NASDAQ: VTRS · Healthcare · Drug Manufacturers - Specialty & Generic
#32 of 1,418 Healthcare companies by revenue37th-percentile growth
EA Score
63CFH 66DQ 57GM 47SS 98
v0.1 · 65/100 weight · provisional
↑ listing tenure, market scale · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$14.6B
Rev growth YoY (TTM)
+1.6%
Net income (FY)
-$3.5B
Employees
30,000
as of 2026-08-05
Market cap
$20.6B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.3B$14.3B2025
Net income-$3.5B-$3.5B2025
Operating income-$2.7B-$2.7B2025
Total assets$37.2B$37.2B2025
Liabilities$22.5B$22.5B2025
Equity$14.7B$14.7B2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Brands64%
Generics36%
By geography
Developed Markets60%
Greater China16%
Emerging Markets16%
Japan, Australia and New Zealand8%
The read
What is Viatris Inc.’s revenue?
Viatris Inc. booked $14.3B in FY2025 revenue, contracting 3.0% year over year — slower than 63% of Healthcare companies we track, at a -24.7% net margin.
Peers · Healthcare
Universal Health Services, Inc.83B+IQVIA Holdings Inc.79B+Regeneron Pharmaceuticals, Inc.85ALabcorp Holdings Inc.84B+DaVita Inc.77B+Henry Schein, Inc.77B+Neighbors
Washington →Key facts
CEOScott Andrew Smith
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCanonsburg, PA
ExchangeNASDAQ: VTRS
Employees30,000
IPO date1980-03-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.